3-n-Butylphthalide (NBP) [(±)-3-butyl-1(3H)-isobenzofuranone] is an anti-cerebral ischemia drug. Moderate hepatotoxicity has been observed in clinic.
Introduction
Sulfation catalyzed by the sulfotransferase (SULT, EC 2.8.2) superfamily is an important phase II conjugation in the metabolism of xenobiotics, modulation of biological activity, and inactivation and elimination of potent endogenous chemicals, including thyroid hormones, steroids and monoamine neurotransmitters (Weinshilboum, 1986; Coughtrie et al., 1998; Wang and James, 2006) . The sulfation pathway is generally considered as a detoxification pathway making more polar and water-soluble products, thereby aiding their excretion via kidneys or bile (Gamage et al., 2006) . However, in certain cases, sulfation increases toxicity. Currently, it is increasingly recognized that sulfation mediates the bioactivation of many drugs, such as tamoxifen and nevirapine, via the formation of highly reactive electrophilic species attributed to the good leaving property of the sulfate group Glatt, 2000; Kim et al., 2005; Sharma et al., 2013) .
3-n-Butylphthalide (NBP), [(±)-3-butyl-1(3H)-isobenzofuranone] is an oral agent
for the treatment of cerebral ischemia (Yan et al., 1998; Chong and Feng, 1999; Peng et al., 2008) . The recommended oral dose of NBP is 200 mg taken thrice a day and the treatment course is 10 days (NBP Pharmaceutical Co., 2009 ). In the 6-month toxicity studies in Sprague-Dawley rat (250 and 500 mg/kg/day NBP) and Beagle dogs (500 mg/kg/day NBP), hepatoxicity was observed, indicated by the elevations in serum enzyme levels of ALT (alanine aminotransferase), ALP (alkaline phosphatase), and GGT (γ-glutamyl transferase) (NBP Pharmaceutical Co., 2009) . Histopathologically, the livers showed evidence of slight hypertrophy and vacuolar degeneration in focal hepatocytes (NBP Pharmaceutical Co., 2009) . Moderate hepatotoxicity, indicated by ALT elevations, was also reported in humans after chronic medication of NBP (Cui et al., 2005; Cui et al., 2008; NBP Pharmaceutical Co., 2009; Xu and Zhao, 2011) . And This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on January 27, 2014 as DOI: 10.1124/dmd.113.056218 at ASPET Journals on August 28, 2017 dmd.aspetjournals.org Downloaded from #56218 5 the incidence ranged from 3.0% to 17.5% in Phase II, III, and IV clinical trials (Cui et al., 2005; Cui et al., 2008; NBP Pharmaceutical Co., 2009; Cui et al., 2013) . Our previous studies demonstrated that after single administration of 200 mg NBP soft capsules, NBP undergoes extensive metabolism in humans (Diao et al., 2013a; Diao et al., 2013b) . No parent drug was detected in the urine or feces, and urinary metabolites accounted for about 81.6% of the administrated dosage (Diao et al., 2013a) . Out of the various urinary metabolites, an N-acetylcysteine (NAC) conjugated metabolite, i.e., 3-NAC-NBP, which accounted for 4.7±2.1% of the administrated dose, drew our concern (Diao et al., 2013a) .
NAC conjugates are generally considered to be derived from glutathione (GSH) conjugates through subsequent hydrolytic cleavage of glutamic acid and glycine residues to an S-substituted cysteine (Cys), which undergoes further N-acetylation, i.e., the classical mercapturic acid pathway (Clapp and Young, 1970; Renner and Nguyen, 1984; Poon et al., 2001) . Abundant excretions of NAC or GSH conjugates in urine are convincing evidence for the presence of reactive metabolites or intermediates, which may be associated with hepatotoxicity (Gopaul et al., 2000; Poon et al., 2001; Rinaldi et al., 2002) .
The aim of the present study is to illuminate the formation mechanism of reactive metabolite and evaluate its potential association with the hepatotoxicity of NBP.
This article has not been copyedited and formatted. The final version may differ from this version. (Shijiazhuang, Hebei, China) . GSH, NAC, Cys, NADPH, 2,6-dichloro-4-nitrophenol (DCNP), quercetin, dithiothreitol (DTT), 3'-phosphoadenosine-5'-phosphosulfate (PAPS), and L-buthionine-sulfoximine (BSO) were purchased from Sigma-Aldrich Co. (St. Louis, MO). 3-OH-NBP was synthesized as described in the literature with some modifications (Yang et al., 2007) . Fresh rat liver and kidney homogenates were prepared from male Sprague−Dawley rats as previously described (Bjorge and Baillie, 1991) . 3-GSH-NBP was isolated and purified from the biotransformation of 3-OH-NBP (50 μ M) in fresh rat liver homogenate supplemented with GSH (1.5 mM).
3-NAC-NBP was purified from human urine and subjected to NMR analysis. Human liver microsomes (HLM), human liver cytosol (HLC), human liver 9,000g supernatant (S9), rat liver microsomes (RLM), rat liver cytosol (RLC), rat kidney microsomes (RKM), rat kidney cytosol (RKC), and rat kidney S9 were supplied by BD Gentest (Woburn, MA). Recombinant human SULT (SULT1A1*1, SULT1A1*2, SULT1A2, SULT1A3, SULT1B1, SULT1E1, and SULT2A1) were purchased from Cypex (Dundee, Scotland, UK). Cryopreserved primary human hepatocytes were obtained from Xeno-Tech LLC (Lenexa, KS).
Trapping of reactive metabolite using GSH, Cys, and NAC. The HLM, HLC, human liver S9, RLM, RLC, or rat liver S9 were thawed carefully on ice prior to the experiment. Fresh rat liver and kidney homogenates were kept on ice during preparation. The substrates, NBP and 3-OH-NBP, were dissolved in methanol and diluted with phosphate-buffered saline (PBS, pH 7.4, 100 mM) containing MgCl 2 (0. (Mulder and Scholtens, 1977; Walle et al., 1995; Wang et al., 2009 ). The samples were subjected to the same pretreatment procedure as described in a previous study "Trapping of reactive metabolite using GSH, Cys, and NAC". The reconstituted solution was then analyzed by UPLC-Q/TOF MS (Waters). Cytotoxicity of 3-OH-NBP in primary human and rat hepatocytes. Cryopreserved primary human hepatocytes were revived according to the protocol and seeded in 96-well collagen I-coated plates (BD Gentest) at a density of 3 × 10 5 cells/ml. Primary rat hepatocytes were prepared as a previously described two-step collagenase perfusion technique with the following modifications: perfusion buffer and digestion buffer flow rates were set constant at 17.5 and 15.0 ml/min, respectively; collagenase type II was used instead of type I in our study (Seglen, 1976; Mohamed and Kaddoumi, 2013; Shukla et al., 2013) . The fresh primary rat hepatocytes were also seeded in the 96-well collagen I-coated plates at a density of 3 × 10 5 cells/ml. The primary human or rat hepatocytes were then cultured for 24 h prior to the addition of 3-OH-NBP. All cell incubations were performed in triplicate and maintained at 37°C
Incubation of 3-OH-NBP with recombinant human
This article has not been copyedited and formatted. The final version may differ from this version. Iwamura et al., 2011) and measured at 450 nm. The absorbance of the treated cells was compared with that of the control, in which the cells were exposed only to the vehicle and considered as 100% viable.
The effects of several SULT inhibitors or GSH depletor on their modulation of cytotoxicity caused by 3-OH-NBP were also evaluated. These inhibitors included non-specific SULT inhibitor DCNP (10 Statistical analysis. Formation rate of 3-GSH-NBP in subcellular fractions and recombinant human SULT was calculated as
where C1 (μM) and C2 (mg/ml) are the concentrations of 3-GSH-NBP and protein in the incubation sample, respectively, V (μl) is the incubation volume, T (min) is the incubation time.
Data from culture of hepatocytes are presented as mean ± SD values. Differences
This article has not been copyedited and formatted. The final version may differ from this version. Primary fragment ions of 3-NAC-NBP were 221.065 and 177.075, which were attributed to the cleavage of the C−S bond (Fig. 1B) . Product ion scan of 3-GSH-NBP revealed fragment ions at m/z 272.088 and 254.079; cleavage occurred mainly on C−S bond and the GSH moiety (Fig. 1D) .
To elucidate the formation pathway of 3-NAC-NBP and its precursor, 3-GSH-NBP, NBP and 3-OH-NBP were separately incubated in liver microsomes, liver cytosol, or liver S9 from humans and rats in the presence of NADPH. GSH, NAC, and Cys were also added in the medium as trapping agents. However, the scenario became quite different in the freshly prepared rat liver homogenate incubation system (fresh human liver homogenate was not assayed because of its commercial unavailability and ethical issues). As shown in Fig. 2 (left) , when NBP was used as the substrate, 3-GSH-NBP was detected at trace amount (mass intensity, 60.6) with the addition of NADPH and GSH. No 3-NAC-NBP or 3-Cys-NBP was observed in the presence of NADPH and NAC or Cys, respectively.
However, when 3-OH-NBP was used as the substrate, 3-GSH-NBP, 3-NAC-NBP, and 3-Cys-NBP were formed (Fig. 2, right) . The yield of 3-GSH-NBP was 39.3-fold higher using 3-OH-NBP as the substrate than using NBP. Notably, the yield of 3-GSH-NBP (mass intensity, 2380) was much higher than those of 3-NAC-NBP (mass intensity, 83.8) and 3-Cys-NBP (mass intensity, 509). In terms of UPLC-UV analysis, the peak area of 3-GSH-NBP was 2.1-fold higher than the summed areas of 3-NAC-NBP and 3-Cys-NBP.
Formation of 3-GSH-NBP in incubation with PAPS.
To facilitate the interpretation of the underlying formation mechanism of the NBP reactive metabolite, GSH was employed as the trapping agent because of its much stronger nucleophilicity compared with NAC and Cys (Fig. 2) . In the presence of PAPS, 3-GSH-NBP was detected in HLC and RLC with formation rates of 0.74 and 5.97 pmol/min/mg protein, respectively (Figs. 3A and 3B). Trace amount of 3-GSH-NBP was also generated in HLM and RLM fortified with PAPS. In the absence of PAPS, almost no 3-GSH-NBP was observed in HLC or RLC. PAPS-dependence suggested the involvement of SULT (Gong et al., 2012; Yalcin et al., 2013) . Selective inhibitors of SULT were estimated to further confirm the role of SULT in mediating the formation of 3-GSH-NBP. As shown in Fig 
Identification of SULT isoenzymes responsible for 3-OH-NBP bioactivation. To identify the SULT isoform(s) involved in 3-GSH-NBP formation, a panel of seven
recombinant human SULTs (SULT1A1*1, SULT1A1*2, SULT1A2, SULT1A3, SULT1B1, SULT1E1, and SULT2A1) was screened for their activities. Results indicated that all tested SULT isoforms could mediate the yield of 3-GSH-NBP (Fig.   4A ). The formation rate of 3-GSH-NBP ranged from 1.94 to 10.58 pmol/min/mg protein, following a decreasing order of SULT1A1*2 (Fig. 4A) . After the normalization of 3-GSH-NBP formation rate to the native content of each SULT isoform in human liver cytosolic fractions (Riches et al., 2009 ), sulfation of 3-OH-NBP was mainly catalyzed by SULT1A1 (Fig. 4B ), and to a lesser extent, by SULT1B1. Another two isoforms, SULT1E1 and SULT2A1 also made minor contribution to the sulfation. (Fig. 5A) . However, dose-dependent toxicity was observed after the treatment of 3-OH-NBP in primary rat hepatocytes (Fig. 5B) . Notably, cell viability in the group treated with 400 μ M 3-OH-NBP was as low as 27% that of the vehicle group (Fig. 5B) . The calculated IC 50 of 3-OH-NBP on the rat hepatocytes viability was approximately 168 μ M (calculated by SPSS).
Cytotoxicity and bioactivation of 3-OH-NBP in primary human and rat hepatocytes. Bioactivation of xenobiotics via sulfation involves the leaving of the
To determine the mechanisms of cytotoxicity, SULT inhibitors DCNP and quercetin, or GSH depletor BSO, were added in primary rat hepatocytes culture medium to examine their effects on the modulation of the toxic response. As displayed in S1 ).
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Discussion
NBP undergoes extensive metabolism prior to its excretion as metabolites in human or rat urine. High proportion of 3-NAC-NBP, a mercapturic acid metabolite, was observed, which might be associated with formation of reactive metabolites and sequential toxicity. Herein, we proposed a metabolic bioactivation pathway of NBP.
We initially incubated NBP and 3-OH-NBP in liver microsomes, liver cytosol or liver S9 from humans and rats with NADPH and trapping agents GSH, NAC, and Cys.
No 3-GSH-NBP, 3-NAC-NBP, and 3-Cys-NBP were formed in these subcellular fraction incubations. However, when NBP was incubated in freshly prepared rat liver homogenate, except for trace amount of 3-GSH-NBP, no 3-NAC-NBP and 3-Cys-NBP were formed. When 3-OH-NBP was incubated in fresh rat liver homogenate, the formation of 3-GSH-NBP was 39.3-fold higher than using NBP as the substrate. Moderate formation of 3-NAC-NBP and 3-Cys-NBP was also observed.
The most likely reason is that the freshly prepared rat liver homogenate intactly contains all drug metabolizing enzymes and prerequisite co-factors. Hence, 3-GSH-NBP was concluded to be generated from 3-OH-NBP, instead of directly from NBP. Therefore, 3-OH-NBP was used as the substrate in subsequent tests to elucidate the bioactivation pathway. Furthermore, it can also be concluded that HLM, HLC or human liver S9 may lack some cofactors that are obligatory for certain enzyme(s) responsible for mediating 3-GSH-NBP generation.
In the present study, the lacking cofactor was PAPS because the 3-GSH-NBP formation in HLC was PAPS-dependent (Fig. 3A) , indicating the involvement of SULT. Trace amount of 3-GSH-NBP was also detected in PAPS-fortified HLM probably because of the contamination of microsomes with minor cytosolic enzymes.
Addition of SULT general inhibitor DCNP or quercetin potently suppressed the yield
This article has not been copyedited and formatted. The final version may differ from this version. of 3-GSH-NBP in HLC (Fig. 3A) , further confirming the contribution of SULT to the formation of 3-GSH-NBP. Similar formation profile of 3-GSH-NBP was observed in RLM and RLC (Fig. 3B) . Notably, the formation rate of 3-GSH-NBP in RLC (5.97
pmol/min/mg protein) was approximately 8.1 times higher than that in HLC (0.74 pmol/min/mg protein), indicating higher SULT activity in RLC than in HLC. This result is consistent with higher urinary excretion rate of 3-NAC-NBP in rats than in humans (8.7% vs. 4.7%). The species difference on SULT activity was also observed on the formation of tamoxifen-DNA adducts which was catalyzed via O-sulfation of hydroxytamoxifen (Kim et al., 2005) .
Reaction phenotyping analysis with seven recombinant human SULTs demonstrated that SULT1A1 made the largest contribution to the formation of 3-GSH-NBP, and to a less extent by, SULT1B1, SULT1E1, and SULT2A1. The bioactivation pathway of NBP was proposed to be through the sulfation of its major metabolite 3-OH-NBP as shown in Fig. 7 . Genetic polymorphism of SULT1A1 was reported with three allelic variants, i.e., SULT1A1*1, SULT1A1*2, and SULT1A1*3 (Carlini et al., 2001) . The allele frequency ratio of SULT1A1*1:*2:*3 was 0.656:0.332:0.012 in Caucasians, 0.477:0.294:0.229 in African Americans, and 0.914:0.080:0.006 in Chinese, respectively Carlini et al., 2001 ). These three alleles are associated with altered enzymatic activities with general trend of V max values determined in previous studies being *1 > *3 >*2 Nagar et al., 2006) . Although SULT1A1*2 showed 40% lower activity toward the sulfation of troglitazone than SULT1A1*1 (Honma et al., 2002) , nearly equivalent enzymatic activities were observed between SULT1A1*1 and SULT1A1*2 toward the formation of 3-GSH-NBP (Fig. 4A) . The SULT1A1*3 was not assayed here because of its commercial unavailability.
This article has not been copyedited and formatted. The final version may differ from this version. In addition to SULT, we also evaluated the role of acetyl transferase in the generation of 3-GSH-NBP, because both sulfate and acetoxy are good leaving groups (Dasaradhi and Shibutani, 1997; Kim et al., 2005) . 3-GSH-NBP was not detected in incubation of 3-OH-NBP with HLC or RLC in the presence of acetyl coenzyme A and GSH, excluding the potential participation of acetyl transferase.
Sulfation and glucuronidation are competitors for the conjugation of 3-OH-NBP. In human urine, 3-OH-NBP glucuronide conjugate was detected, accounting for 3.4% of the administered dose, which was comparable to 3-NAC-NBP (derived from 3-OH-NBP sulfate) (Diao et al., 2013a) . However, 3-OH-NBP glucuronide conjugate was not detected in rat urine, and higher excretion ratio of 3-NAC-NBP was observed, which was probably attributed to the higher SULT activity in rats.
3-NAC-NBP could be formed in two pathways: 1) derived from 3-GSH-NBP through the classical mercapturic acid pathway as mentioned in the "Introduction" section (Poon et al., 2001) ; 2) direct binding of Cys to the cation to yield 3-Cys-NBP, which undergoes further N-acetylation to 3-NAC-NBP. As shown in supplemental was observed in the incubation of 3-OH-NBP with RKM, RKC, rat kidney S9, or fresh rat kidney homogenate in the presence of PAPS and GSH. Therefore, we
proposed that 3-GSH-NBP was generated in the liver and further hydrolyzed to 3-Cys-NBP. The 3-Cys-NBP was later acetylized to 3-NAC-NBP in the kidney and excreted in urine.
Furthermore, cytotoxicity of 3-OH-NBP was evaluated in primary human and rat hepatocytes. 3-OH-NBP was used in this study because it is the start compound of the metabolic bioactivation pathway and also a major metabolite in humans and rats. In hepatocytes. Each column represents the mean of triplicate samples. The controls, in which the cells were exposed only to the vehicle, were considered as 100% viable. *P < 0.05 and ***P < 0.001 versus controls only with vehicle. Each column represents the mean of triplicate samples. *P < 0.05, **P < 0.01, and ***P < 0.001, versus their respective incubations without inhibitors or depletor.
